Home > Name List By b > Blood-coagulationfactor LACI (human clone lP9 protein moiety reduced), N-L-alanyl-

CAS No 148883-56-1 , Blood-coagulationfactor LACI (human clone lP9 protein moiety reduced), N-L-alanyl-

  • Name: Blood-coagulationfactor LACI (human clone lP9 protein moiety reduced), N-L-alanyl-
  • Synonyms: Proteinase inhibitor, [alanyl] TFPI (human); Blood-coagulation factor lipoproteinassociated coagulation inhibitor (human clone lP9 protein moiety reduced), N-L-alanyl-; LACI;Blood-coagulationfactor LACI (human clone lP9 protein moiety reduced), N-L-alanyl-; SC 59735;1:PN: WO2009129164 SEQID: 2 claimed protein; Tifacogin;
  • CAS Registry Number:
  • Flash Point: 139.2°C
  • Boiling Point: 306.5°Cat760mmHg
  • Density: 1.121g/cm3
  • Refractive index: 1.603
  • Flash Point: 139.2°C
  • Molecular Weight: 203.3
  • InChI: InChI=1/C12H13NS/c1-2-5-11(6-3-1)9-13-10-12-7-4-8-14-12/h1-8,13H,9-10H2
  • Molecular Formula: C12H13NS
  • Molecular Structure:CAS No:148883-56-1 Blood-coagulationfactor LACI (human clone lP9 protein moiety reduced), N-L-alanyl-

Select to

148883-56-1 2-THIENYL N-BENZYL METHYL AMINE

  • China Nanjing Chemlin Chemical Industry Co.,Ltd. [Manufacturer]
  • Tel: +86 25 8369-7070/ +86 138 51816776 (Mobile)
  • Fax: +86 25 8345-3275
  • Address: Rm.902 Longyin Plaza,
    No. 217 Zhongshan Rd.
    (N)Nanjing 210009,China null,nullChina
Contact Supplier

148883-56-1 Tifacogin

  • Tifacogin, Min 99%
  • China Finechemie Co., Ltd. [Manufacturer]
  • Tel: +86-23-99186710
  • Fax: +86-23-99186729
  • Address: 28th Floor Mordern Building,New-Tech Zone400020 ChongqingCHINA Chongqing,nullChina
Contact Supplier

Select to

References of Blood-coagulationfactor LACI (human clone lP9 protein moiety reduced), N-L-alanyl-
Title: Tissue Factor Pathway Inhibitor
Synonyms: TFPI; lipoprotein-associated coagulation inhibitor; LACI
Literature References: Endogenous inhibitor of the tissue factor mediated pathway of blood coagulation. Glycoprotein containing 276 amino acid residues; mol wt ~42 kDa. Structure consists of an acidic amino terminal region followed by three tandem Kunitz-type protease inhibitory domains and a basic carboxy terminal region. Forms a quaternary inhibitory complex with tissue factor, factor VIIa and factor Xa to block the formation of thrombin from prothrombin. Isoln of factor produced by hepatoma cells: G. J. Broze, Jr., J. P. Miletich, Proc. Natl. Acad. Sci. USA 84, 1886 (1987); from human plasma: W. F. Novotny et al., J. Biol. Chem. 264, 18832 (1989). Review of structure and physiology: G. J. Broze, Jr., Annu. Rev. Med. 46, 103-112 (1995); of pharmacology and therapeutic potential: A. K. Lindahl, Cardiovasc. Res. 33, 286-291 (1997); B. Kaiser et al., Emerg. Drugs 5, 73-87 (2000).
 
Derivative Type: Tifacogin
CAS Registry Number: 148883-56-1
CAS Name: N-L-Alanyl-blood coagulation factor LACI (human clone lP9 protein moiety reduced)
Manufacturers' Codes: SC-59735
Literature References: Recombinant human form; differs from the native protein by an additional alanine residue at the amino terminus and is not glycosylated. Prepn by expression in E. coli: G. J. Broze, Jr. et al., EP 318451; eidem, US 4966852 (1989, 1990 both to Monsanto Co.; Washington Univ.); M. E. Gustafson et al., Protein Expression Purif. 5, 233 (1994). Production in Saccharomyces cerevisiae: M. A. Innis, A. A. Creasey, WO 9604377; eidem, US 6103500 (1996, 2000 both to Chiron). Clinical pharmacokinetics: M. J. B. Kemme et al., Clin. Pharmacol. Ther. 67, 504 (2000). Clinical evaluation in sepsis: E. Abraham, Crit. Care Med. 28, Suppl., S31 (2000). Review: N. Sne et al., IDrugs 5, 91-97 (2002).
 
Therap-Cat: Antithrombotic.